Trial Profile
A RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL TO DETERMINE SAFETY AND EFFICACY OF ECULIZUMAB IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION (AMR) IN LIVING DONOR KIDNEY TRANSPLANT RECIPIENTS REQUIRING DESENSITIZATION THERAPY
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 19 Mar 2019 Results published in the American Journal of Transplantation
- 13 Jul 2016 Status changed from active, no longer recruiting to discontinued.
- 13 Apr 2016 This trial is prematurely ended in Germany, Norway, Spain, Italy and completed in Sweden ( end date: 13 Nov 2015).